A month removed from its $1.3 billion agreement to buy PRA, KKR has signed a deal to acquire ReSearch Pharmaceutical Services, planning to merge the two CROs once the transactions close.
Psi, a global CRO out of Switzerland, has expanded into South Africa, touting the nation's diversity and regulatory environment as ideal for patient recruitment and drug development.
More and more companies are eyeing antibody-drug conjugate technology as a path to success in drug development, and Indian contract manufacturer Piramal is spending $2.5 million to expand its ability to supply the in-demand formulation.
Ascendancy Healthcare has tapped Quintiles to help it capitalize on China's booming pharmaceutical market, asking the world's largest CRO to help it choose, develop and market in-licensed therapies.
Dublin's Icon nailed down another strong sales quarter, growing revenue 21% and increasing its full-year expectations.
Clinical Research Advantage is stretching out its business model, buying up Comprehensive Clinical Development's late-stage trials unit and reaching into central nervous system studies.
After years of back-and-forth with the FDA, AMRI believes it's close to getting clear of a 2010 warning letter for its Burlington, MA, plant, completing a reinspection and preparing a final report.
Aesica has struck a deal with Australia's QRxPharma, agreeing to promote the company's abuse-deterrence technology to its clients manufacturing controlled drugs.
For CROs running trials around the globe, amassing loads of data is no sweat, but sharing it with sponsors in disparate countries and keeping it all in line for an eventual regulatory application can be daunting. With that in mind, WuXi PharmaTech, Inflamax Research and CROS NT have all signed deals for eClinical software to manage their trials.
Big Pharma has bought into diagnostic development, and a look at FDA drug approvals over the past year shows that regulators are all aboard for targeted therapies. That makes for a spike in demand for molecular tests, and contract diagnostics developer ResearchDx is upping its capacity to cash in on personalized medicine.
Indiana's CRO Solutions is rolling all of its niche offerings into a single subsidiary, a move the company said will help it better compete in a changing market for research services.
AstraZeneca is casting a wide net across industry and academia for its nearly all outsourced neuroscience unit, now looping in Tufts University's School of Medicine to help develop therapies for ailments like Alzheimer's and Parkinson's.
WuXi PharmaTech and PRA believe they have a bright future in China together, and they've picked up the founding CEO of Theorem Clinical Research to lead them there.
Diagnostics outfit Corgenix is upping its stake in the contract manufacturing game, inking a deal with EDP Biotech to produce a colon cancer test.
China has fast become a huge pillar on the global R&D scene, with local CROs like WuXi PharmaTech and ShangPharma cashing in on demand for clinical trials in the country. But, with the FDA chiding a sloppy Chinese trial run by Bristol-Myers Squibb, Pfizer and PPD, regulators and researchers may think twice before accepting data gathered in the country.
German genomics contractor Blackfield locked up a deal with AstraZeneca, agreeing to provide its computational biology technology to help the drugmaker validate an in-development cancer therapy.
Theorem Clinical Research has inked a deal with Emergo Group, pooling their resources to provide regulatory consultation to makers of medical devices and in vitro diagnostics.
Amid mounting pressure to rein in loosely regulated trials, India has clamped down on approving studies, but the resulting slowdown has scared off CROs, sponsors and other researchers, according to a report.
Following its marked growth over the past few years, New Jersey's Catalent is consolidating its drug delivery operation and teaming up with a drug developer to push a new influenza treatment forward.
More and more, academic researchers are turning to CROs to pitch in on early-stage projects, but schools could better optimize how they use contractors, according to a report in Nature.